Keyphrases
Acetylcholine Receptor Subunit
56%
Aggressive B-cell Lymphoma
28%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
61%
Amyotrophic Lateral Sclerosis
28%
Anti-CD19 chimeric Antigen Receptor T Cells
37%
Ashkenazi
25%
B Cells
37%
Bendamustine
30%
Brain Transcriptome
28%
Breast Cancer
31%
Cell Function
28%
Cell Migration
42%
Chimeric Antigen Receptor T Cells (CAR-T)
48%
Chimeric Antigen Receptor T-cell Therapy
52%
Complete Remission
31%
Complete Response
25%
Confidence Interval
24%
Cyclophosphamide
24%
Disease Progression
24%
FDG PET-CT
32%
Fluorine-18
28%
Fluorodeoxyglucose
28%
Follicular Lymphoma
36%
Gene-deficient Mice
29%
Genotype
27%
Graft-versus-host Disease (GvHD)
32%
Hematological Malignancies
23%
High Risk
23%
Immunoglobulin Genes
28%
Israeli
42%
Large B-cell Lymphoma
30%
Lymphoma Patients
24%
MicroRNA
42%
Mouse Brain
28%
Nicotine
84%
Nicotinic Acetylcholine Receptor (nAChR)
100%
Novel mutation
28%
Oncology Patients
28%
Overall Response Rate
22%
Overall Survival
60%
Parkinson's Disease
53%
Point-of-care
44%
Positron Emission Tomography-computed Tomography (PET-CT)
38%
Progression-free Survival
38%
Relapsed or Refractory
35%
Retrospective Analysis
23%
Rituximab
38%
Seizure
42%
Self-tolerance
28%
Tumor Progression
42%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
14%
Adriamycin Bleomycin Vinblastine Dacarbazine
16%
Allogeneic Stem Cell Transplantation
16%
B Cell
51%
B-Cell Lymphoma
28%
BEACOPP
14%
Bendamustine
21%
Bortezomib
14%
Breast Cancer
28%
Brentuximab Vedotin
14%
Cancer
14%
Cardiovascular Effect
14%
Cell Migration
28%
Cell Transplantation
14%
Chimeric Antigen Receptor T-Cell
60%
Chimeric Antigen Receptor T-Cell Immunotherapy
52%
Chimeric Antigen Receptor T-Cell Therapy
14%
Conditioning
14%
COVID-19
16%
COVID-19 Vaccine
14%
Cyclophosphamide
24%
Cyclosporine
14%
Deoxyglucose
28%
Diseases
43%
Fludarabine
14%
Fluorine-18
28%
Follicular Lymphoma
40%
Gemcitabine
14%
Graft Versus Host Reaction
14%
Growth Factor
23%
Hodgkin's Lymphoma
42%
Humoral Immunity
14%
Large-Cell Lymphoma
49%
Lidocaine
14%
Lymph Duct
15%
Messenger RNA
15%
Meta-Analysis
14%
Metastatic Carcinoma
25%
microRNA
18%
Multiple Myeloma
14%
Neoplasm
22%
Non-Hodgkin Lymphoma
61%
Overall Survival
75%
Polyethylene Terephthalate
24%
Positron Emission Tomography-Computed Tomography
70%
Progression Free Survival
52%
Quality of Life
14%
Rituximab
38%
Salvage Therapy
30%
T Cell
22%
Biochemistry, Genetics and Molecular Biology
Actin
16%
Allele
37%
B Cell
16%
Cancer Cell
24%
Carcinogenesis
16%
Cell Function
16%
Cell Migration
42%
Emerin
14%
Epidermal Growth Factor
17%
Epidermal Growth Factor Receptor
23%
Erythropoietin
14%
Exon
36%
Gastrulation
21%
Gemcitabine
14%
Gene Mutation
21%
Genetic Disorder
14%
Genotyping
41%
Glucocorticoid
14%
Growth Factor
25%
Growth Factor Signaling
15%
Haplotype
23%
Homozygosity
15%
Humoral Immunity
14%
IGHV@
14%
Leukocyte
14%
LRRK2
20%
Mediator
14%
Messenger RNA
34%
Metastasis Suppressor
14%
MicroRNA
60%
Microsatellite Instability
14%
Nicotinic Acetylcholine Receptor
32%
Non-Coding RNA
14%
Overall Survival
35%
Promoter Region
14%
Proteomics
16%
Quantitative Technique
14%
RNA Sequence
18%
Scanning Electron Microscopy
14%
Single-Nucleotide Polymorphism
14%
Small Intestine
14%
Stem Cell
16%
Synapsin I
14%
T Cell
33%
Transcription
21%
Transcription Factors
18%
Transcriptome
34%
Transcriptomics
30%
Tumor Progression
44%
Tumor Suppressor Protein
18%